Clinical trials recruiting in Cottbus, Germany

Phase breakdown

Conditions recruiting in Cottbus, Germany

Recruiting trials in Cottbus, Germany

• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
  NCT06830720 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Non-interventional, Prospective Study With Benralizumab
  NCT06422078 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
  NCT07071519 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
  NCT06750289 · Phase: Phase 3 · Ages: 12 Years to 75 Years · Sex: All (male and female)
• Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
  NCT06517719 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: Male
• Register Schweres Asthma - German Asthma Net e.V.
  NCT06035289 · Phase: Not specified · Ages: 6 Years and older · Sex: All (male and female)
• Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
  NCT07486960 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
  NCT07301736 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Cottbus, Germany?

15 recruiting trials have at least one study site in Cottbus, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.